A Big Dose of Pharma Plays

Are these 5 drugmakers BUYs or NOT? ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

BROUGHT TO YOU BY MANWARD PRESS Buy This, Not That: A Big Dose of 5 Big Pharma Stocks SPONSORED The Mysterious VC Firm Behind Nvidia's Secret Weapon In 1999, Sutter Hill Ventures made a bold bet on Nvidia before anyone had heard of it. Now, they're going all-in on Nvidia's hush-hush partner that's powering their new Blackwell chip. Discover the little-known company that's attracting massive investments from the visionaries behind Nvidia's 100,000% rise. Unlock the hidden key to AI's future.   A Note From Amanda: In this edition of Buy This, Not That... Shah's looking at a sector that outperforms during the months of July and August. But before you dive in... you need to see Shah's just released research on what he's calling "Undefeated Stocks" - stocks that produce gains like clockwork. If you're interested in getting his No. 1 pick for August - a stock that has averaged double-digit gains in the month of August for five straight years - click here. Shah Gilani Chief Investment Strategist The healthcare sector pumps trillions of dollars through our economy's veins each year. But not all healthcare stocks deserve a spot in your portfolio. From weight loss wonder drugs to household staples... we're putting five pharmaceutical heavyweights to the test. SPONSORED The Next Big Short Is Here! Real estate crashes, when they occur, have proven to create some of the biggest fortunes in history. In 2008, John Paulson made $20 billion shorting the housing crash. In 2020, Carl Icahn made $1.3 billion shorting shopping malls. Today, the $21 trillion commercial real estate market is in free fall. Professional traders have already made $600 million in a single day. And the biggest trades are setting up now. Go here now for your shot at a historic opportunity.   Are their stock charts showing signs of good health... or do they need intensive care? We're looking at a pharma giant with a sky-high P/E ratio... a dividend darling that could be living beyond its means... one that might need to call a Code Blue on its finances... and more. Which of these pharma stocks hands out a prescription for portfolio health? And which ones should be quarantined? It's all in the latest episode of Buy This, Not That... your exclusive guide to the stocks that are worthy of your money - NOW. Click here or on the thumbnail below to dive in. WATCH THE VIDEO (WITH TRANSCRIPT) Cheers, Shah SPONSORED 4,735% Revenue Surge: The Linchpin of Nvidia's AI Dominance? As Nvidia's new Blackwell chip sparks an AI revolution, one company is poised to skyrocket. This unsung hero's revenue could soar up to 4,735% in the next 12 months as tech titans line up to secure their groundbreaking technology. Early investors could see life-changing gains as this story unfolds. Don't miss your chance to ride the AI mega-trend.   Want more content like this? YES NO

Shah Gilani Shah Gilani is the Chief Investment Strategist of Manward Press. Shah is a sought-after market commentator... a former hedge fund manager... and a veteran of the Chicago Board Options Exchange. He ran the futures and options division at the largest retail bank in Britain... and called the implosion of U.S. financial markets (AND the mega bull run that followed). Now at the helm of Manward, Shah is focused tightly on one goal: to do his part to make subscribers wealthier, happier and freer.

You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Total Wealth. © 2024 Manward Press, LLC | All Rights Reserved

Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.